Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

• Published in: Journal of clinical oncology Vol. 25; no. 27; pp. 4270 - 4277
• Main Authors: HEYMACH, John V, JOHNSON, Bruce E, KENNEDY, Sarah J, HOU, Jeannie, HERBST, Roy S, PRAGER, Diane, CSADA, Edit, ROUBEC, Jaromir, PESEK, Milos, SPASOVA, Irena, BELANI, Chandra P, BODROGI, Istvdn, GADGEEL, Shirish
• Format: Journal Article
• Language: English
• Published: Baltimore, MD American Society of Clinical Oncology 20.09.2007; Lippincott Williams & Wilkins
• Subjects: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Carcinoma, Non-Small-Cell Lung - drug therapy; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Lung Neoplasms - drug therapy; Male; Medical sciences; Middle Aged; Piperidines - administration & dosage; Placebos; Pneumology; Quinazolines - administration & dosage; Taxoids - administration & dosage; Tumors; Tumors of the respiratory system and mediastinum; Antineoplastic agent; Lung disease; Vandetanib; Respiratory disease; Lung cancer; Docetaxel; Malignant tumor; non-small cell lung carcinoma; Randomization; Cancerology; Treatment; Taxane derivatives; Phase II trial; Placebo; Bronchus disease; Antimitotic
• ISSN: 0732-183X; 1527-7755
• DOI: 10.1200/JCO.2006.10.5122

Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor-2 and epidermal growth factor receptor kinase activity. The activity of vandetanib plus docetaxel was assessed in patients with previously treated non-small-cell lung cancer (NSCLC). This two-part study comprised an open-label run-in phase and a double-blind randomized phase. Eligible patients had locally advanced or metastatic (stage IIIB/IV) NSCLC after failure of first-line platinum-based chemotherapy. The primary objective of the randomized phase was to prolong progression-free survival (PFS) in patients receiving vandetanib (100 or 300 mg/d) plus docetaxel (75 mg/m2 intravenous infusion every 21 days) versus placebo plus docetaxel. The study was designed to have more than 75% power to detect 50% prolongation at a one-sided significance level of P < .20. Secondary objectives included objective response rate, overall survival, safety and tolerability. In the randomized phase (n = 127), median PFS was 18.7 weeks for vandetanib 100 mg plus docetaxel (n = 42; hazard ratio v docetaxel = 0.64; one-sided P = .037); 17.0 weeks for vandetanib 300 mg plus docetaxel (n = 44; hazard ratio v docetaxel = 0.83; one-sided P = .231); and 12 weeks for docetaxel (n = 41). There was no statistically significant difference in overall survival among the three treatment arms. Common adverse events included diarrhea, rash, and asymptomatic prolongation of corrected QT (QTC) interval. The primary objective was achieved, with vandetanib 100 mg plus docetaxel demonstrating a significant prolongation of PFS compared with docetaxel in relation to the prespecified significance level. On the basis of these encouraging data, phase III evaluation of vandetanib 100 mg plus docetaxel in second-line NSCLC has been initiated.